Cytek Biosciences (NASDAQ:CTKB) Issues Quarterly Earnings Results

by · The Cerbat Gem

Cytek Biosciences (NASDAQ:CTKB – Get Free Report) announced its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.07), FiscalAI reports. Cytek Biosciences had a negative net margin of 36.25% and a negative return on equity of 9.81%. The firm had revenue of $44.14 million for the quarter, compared to analyst estimates of $44.23 million.

Here are the key takeaways from Cytek Biosciences’ conference call:

  • Q1 revenue was $44.1M (up 6% YoY), led by a strong U.S. rebound with U.S. revenue of $24.4M (up 32%), indicating recovering instrument demand.
  • Recurring revenue (reagents + service) reached $18.4M and now represents 35% of trailing 12‑month revenue (19% YoY growth); installed base grew by 125 units to 3,789 and the Aurora Evo is driving product traction.
  • Profitability worsened—GAAP net loss widened to $18.9M (from $11.4M) and adjusted EBITDA loss was $9.1M, driven by a 13% rise in operating expenses and a $5.6M increase in G&A largely from patent litigation and consulting.
  • Management reaffirmed full‑year guidance of $205M–$212M (2%–5% growth), holds $262.2M in cash and expects to deliver positive adjusted EBITDA for full year 2026.

Cytek Biosciences Stock Down 6.3%

Shares of Cytek Biosciences stock traded down $0.31 on Friday, hitting $4.61. 1,361,764 shares of the company traded hands, compared to its average volume of 600,220. The company has a 50-day moving average price of $4.48 and a 200 day moving average price of $4.75. Cytek Biosciences has a 12-month low of $2.37 and a 12-month high of $6.18. The company has a market cap of $595.34 million, a PE ratio of -8.09 and a beta of 1.22.

Analyst Upgrades and Downgrades

Several analysts have issued reports on CTKB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytek Biosciences in a research note on Friday, March 27th. TD Cowen restated a “buy” rating on shares of Cytek Biosciences in a report on Thursday, January 8th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Cytek Biosciences presently has an average rating of “Hold” and an average target price of $5.38.

Check Out Our Latest Report on CTKB

Hedge Funds Weigh In On Cytek Biosciences

Several institutional investors and hedge funds have recently modified their holdings of CTKB. AQR Capital Management LLC grew its holdings in shares of Cytek Biosciences by 394.4% during the 1st quarter. AQR Capital Management LLC now owns 653,277 shares of the company’s stock valued at $2,620,000 after acquiring an additional 521,135 shares in the last quarter. Jane Street Group LLC boosted its holdings in Cytek Biosciences by 412.2% in the first quarter. Jane Street Group LLC now owns 344,169 shares of the company’s stock worth $1,380,000 after purchasing an additional 276,972 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Cytek Biosciences in the first quarter worth $162,000. Strs Ohio bought a new stake in Cytek Biosciences in the first quarter worth $105,000. Finally, Creative Planning boosted its holdings in Cytek Biosciences by 455.4% in the second quarter. Creative Planning now owns 55,677 shares of the company’s stock worth $189,000 after purchasing an additional 45,652 shares in the last quarter. 69.46% of the stock is currently owned by hedge funds and other institutional investors.

About Cytek Biosciences

(Get Free Report)

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.

See Also